CorDx

Illumina is improving human health by unlocking the power of the genome. The company provides sequencing and array technologies that fuel genomic discoveries, enabling life-changing breakthroughs in cancer research, reproductive health, genetic disease understanding, and translational and consumer genomics. As a global genomics leader, Illumina innovates to make genomics more accessible to researchers, clinicians, and patients worldwide. Founded in 1998 and headquartered in San Diego, California, Illumina develops integrated systems for the analysis of genetic variation and function. The company's comprehensive portfolio spans high-throughput sequencing platforms like NovaSeq X and NextSeq systems, microarray scanners, library preparation kits, and informatics solutions including BaseSpace Sequence Hub and DRAGEN. By empowering researchers and clinicians with tools that improve cancer treatments, change disease trajectories, and protect future generations, Illumina is transforming the future of precision health and making genomics useful for all.

In 2023, a group of visionary scientists and investors recognized that drug discovery remained an expensive, time-consuming process with high failure rates. Despite advances in AI, the pharmaceutical industry was still struggling to translate computational insights into viable medicines. This realization sparked the creation of Xaira Therapeutics - co-founded and incubated by ARCH Venture Partners and Foresite Labs - to build an integrated biotechnology company that would truly harness the transformative power of artificial intelligence for drug discovery. Built on the groundbreaking protein design work of Nobel Laureate Dr. David Baker and his team at the University of Washington's Institute for Protein Design, Xaira brings together advanced AI research, expansive data generation, and robust therapeutic product development. The company emerged from stealth mode in 2024 with over $1 billion in funding, ready to revolutionize how we treat disease by making predictions about the right biology to target, the best therapeutics to modulate those targets, and the patients who will benefit most. With offices in South San Francisco, Seattle, and London, Xaira is shifting drug discovery from an empirical science to a precise engineering discipline.

Invivoscribe is a global leader in precision oncology diagnostics, dedicated to improving lives with standardized molecular testing solutions. For over 30 years, the company has pioneered the international standardization of molecular and flow cytometry testing, expanding access to advanced cancer therapies worldwide. Invivoscribe develops and manufactures a comprehensive portfolio of molecular assays, reagents, controls, and bioinformatics tools under ISO 13485 design control, supporting more than 700 clinical laboratories in over 160 countries. The company's Streamlined CDx (companion diagnostic) model accelerates the development of novel therapeutics, enabling personalized approaches to patient care. Invivoscribe's products consistently surpass industry and regulatory standards, playing a crucial role in identifying, stratifying, and monitoring hematologic cancers. Through its subsidiary, the Laboratory for Personalized Molecular Medicine (LabPMM), Invivoscribe offers extensive clinical diagnostic and biopharma services, providing globally standardized flow cytometry and molecular testing services for pharmaceutical and healthcare organizations across the U.S., Europe, and Asia.

Precision Resource operates over 100 fineblanking presses - the largest such fleet in the world. Our vertically integrated manufacturing capabilities span fineblanking, precision machining, additive manufacturing, assembly, and finishing. We produce mission-critical components for the automotive, aerospace, medical, electronics, heavy-duty, and military & defense industries. This global infrastructure enables us to deliver high-precision metal components that meet the most demanding specifications for market-leading customers across six continents. Founded in 1947, we maintain facilities across the United States, Canada, China, Mexico, Slovenia, and Germany. Our technical center in Cambridge, Ontario drives innovation in metal additive manufacturing and fuel cell bipolar plates. The average Precision Resource employee stays with the company for ten years, with some team members exceeding four decades of service. This expertise allows us to accelerate development and optimize production, taking projects seamlessly from concept to delivery while maintaining the quality standards our customers require.

Re:Build Manufacturing is a U.S.-based family of industrial businesses founded in 2020 to design, engineer, and manufacture complex products across the full production lifecycle - from initial concept and prototyping through to high-volume output. Operating across more than 14 facilities and one million square feet of advanced manufacturing capacity, the company brings together over 400 engineers and more than 1,200 technical experts. Its stated mission is to ensure that the next generation of important products are made in America. The company serves customers across five core industry verticals: aerospace and defense, medical, electrification, energy and environment, and robotics and automation. It works with both startups and established companies, offering end-to-end capabilities that span integrated design, engineering, scalable manufacturing, and rigorous quality management. To date, Re:Build has successfully launched more than 800 specialized products for its customers. Re:Build's model combines organic operational capability with strategic mergers and acquisitions to build out its portfolio of industrial businesses. This structure allows it to deploy enabling technologies and manufacturing expertise across a coordinated group of companies rather than a single entity. Operational superiority and adaptability to how individual customers work are positioned as central to how the business operates.

AMTSOL delivers technology solutions for pharmaceutical and biotechnology manufacturers, specialising in the digitalization and automation of GMP-regulated manufacturing environments. The company's work spans the full stack of manufacturing systems - from Level 2 automation through to Level 5 cloud integration and data analytics - and covers the complete project lifecycle, from consultancy and implementation to validation and continuous improvement. Its core service areas include Manufacturing Execution Systems (MES), OT networking, automation, cloud integration, data analytics, and both Computerized System Validation (CSV) and Commissioning, Qualification, and Validation (CQV) services. AMTSOL operates as a vendor-independent, single-partner provider, taking full responsibility for consultancy, project support, and ongoing optimisation across each engagement. GMP compliance and data integrity are central to its delivery model. The company works with pharmaceutical and biotechnology organisations across Singapore, Europe, and the United States, with a focus on Pharma 4.0 adoption and digital transformation. Its stated operational priorities include helping regulated manufacturers increase speed to market and improve operating efficiency.